Cyclerion Therapeutics,Inc. (CYCN)
NASDAQ:CYCN
Total Valuation
Cyclerion Therapeutics has a market cap or net worth of $13.68M. The enterprise value is $10.44M.
Market Cap$13.68M
Enterprise Value$10.44M
Share Statistics
Cyclerion Therapeutics has 4,330,314 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,330,314
Owned by Insiders15.03%
Owned by Institutions2.95%
Financial Efficiency
Cyclerion Therapeutics’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -54.74%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-54.74%
Return on Capital Employed (ROCE)-0.55
Revenue Per Employee2.07M
Profits Per Employee-3.53M
Employee Count1
Asset Turnover0.21
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cyclerion Therapeutics is ―. Cyclerion Therapeutics’s PEG ratio is 0.12.
PE Ratio―
PS Ratio1.97
PB Ratio0.45
Price to Fair Value0.45
Price to FCF-1.24
Price to Operating Cash Flow-3.08
PEG Ratio0.12
Income Statement
In the last 12 months, Cyclerion Therapeutics had revenue of 2.07M and earned -3.53M in profits. Earnings per share was -1.09.
Revenue2.07M
Gross Profit2.07M
Operating Income-4.97M
Pretax Income-3.53M
Net Income-3.53M
EBITDA-4.97M
Earnings Per Share (EPS)-1.09
Cash Flow
In the last 12 months, operating cash flow was -3.31M and capital expenditures 0.00, giving a free cash flow of -3.31M billion.
Operating Cash Flow-3.31M
Free Cash Flow-3.31M
Free Cash Flow per Share-0.77
Dividends & Yields
Cyclerion Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.75
52-Week Price Change23.44%
50-Day Moving Average1.74
200-Day Moving Average2.08
Relative Strength Index (RSI)55.51
Average Volume (3m)162.78K
Important Dates
Cyclerion Therapeutics upcoming earnings date is May 1, 2024, Before Open (Confirmed).
Last Earnings DateFeb 22, 2024
Next Earnings DateMay 1, 2024
Ex-Dividend Date―
Financial Position
Cyclerion Therapeutics as a current ratio of 5.15, with Debt / Equity ratio of 0.00%
Current Ratio5.15
Quick Ratio5.15
Debt to Market Cap0.00
Net Debt to EBITDA0.65
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cyclerion Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cyclerion Therapeutics EV to EBITDA ratio is -0.17, with an EV/FCF ratio of -0.26.
EV to Sales0.41
EV to EBITDA-0.17
EV to Free Cash Flow-0.26
EV to Operating Cash Flow-0.26
Balance Sheet
Cyclerion Therapeutics has $3.24M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.24M billion.
Cash & Marketable Securities$3.24M
Total Debt$0.00
Net Cash$3.24M
Net Cash Per Share$0.75
Tangible Book Value Per Share$2.82
Margins
Gross margin is 100.00%, with operating margin of -239.78%, and net profit margin of -170.11%.
Gross Margin100.00%
Operating Margin-239.78%
Pretax Margin-170.11%
Net Profit Margin-170.11%
EBITDA Margin-239.78%
EBIT Margin-239.78%
Analyst Forecast
The average price target for Cyclerion Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast1371.65%
EPS Growth Forecast64.13%